Arcus Biosciences, Inc. RCUS

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived NYSE

We are a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Our most advanced molecules are in Phase 3 registrational studies for various cancer indications and we expect our next wave of clinical-stage molecules to come from our inflammation and autoimmune disease programs. Our vision is to leverage our internal small-molecule discovery capabilities to create, develop and commercialize highly differentiated therapies that can have a meaningful impact on patients.

The chart below summarizes our current clinical and late pre-clinical stage portfolio:

* Taiho holds exclusive licenses in Japan and certain other Asian countries, excluding China, for casdatifan (the "Taiho Territory").

Last close 18.54 2026-10-23
Market cap $2.36B 2026-06-30 share count
52-week range 17.43 - 31.73

Valuation FY2025 figures against the last close

P/S71.5x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-3.29

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $33.0M$51.0M$37.0M$38.0M$383.0M$78.0M$15.0M$8.4M$1.4M—
R&D $523.0M$448.0M$340.0M$288.0M$257.0M$159.0M$78.5M$49.6M$47.2M$14.2M
SG&A $110.0M$120.0M$117.0M$104.0M$72.0M$43.0M$25.2M$13.6M$7.6M$3.9M
Total operating expenses $633.0M$588.0M$457.0M$392.0M$329.0M$202.0M$103.7M$63.2M$54.9M$18.2M
Operating income -$386.0M-$330.0M-$340.0M-$280.0M$54.0M-$124.0M-$88.7M-$54.9M-$53.4M-$18.2M
Interest expense $8.0M$4.0M$2.0M$2.0M——————
Pre-tax income -$353.0M-$282.0M-$301.0M-$266.0M$55.0M-$123.0M-$84.7M———
Income tax $0$1.0M$6.0M$1.0M$2.0M—————
Net income -$353.0M-$283.0M-$307.0M-$267.0M$53.0M-$123.0M-$84.7M-$49.6M-$53.1M-$18.0M
EPS, basic -3.29-3.14-4.15-3.710.76-2.24-1.93———
EPS, diluted -3.29-3.14-4.15-3.710.71-2.24-1.93-1.43-29.03-20.80
Shares, diluted (wtd. avg.) 107.4M90.1M74.0M72.0M74.0M54.8M43.8M36.4M3.9M3.4M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $222.0M$150.0M$127.0M$206.0M$148.0M$173.4M$57.9M$71.1M$98.4M$65.2M
Short-term investments $759.0M$828.0M$632.0M$803.0M$351.0M$555.2M————
Total current assets $1.01B$1.02B$831.0M$1.07B$1.26B$735.8M$192.7M$258.9M$176.9M—
Property, plant and equipment $40.0M$47.0M$51.0M$35.0M$32.0M$10.8M$9.3M$11.1M$11.2M—
Total assets $1.14B$1.15B$1.09B$1.34B$1.59B$772.3M$203.1M$274.9M$190.5M—
Accounts payable $42.0M$18.0M$17.0M$20.0M$10.0M$15.7M$4.7M$3.1M$3.8M—
Total current liabilities $231.0M$226.0M$184.0M$193.0M$166.0M$121.7M$22.7M$16.9M$12.7M—
Long-term debt $99.0M$48.0M$0———————
Total liabilities ————$750.4M$270.0M$39.3M$40.0M$36.6M—
Retained earnings -$1.49B-$1.13B-$849.0M-$542.0M-$275.0M-$328.2M-$205.3M-$122.8M-$73.2M—
Total equity $631.0M$485.0M$462.0M$657.0M$842.0M$502.0M$164.0M$234.9M-$72.3M-$20.0M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow -$482.0M-$170.0M-$306.0M$438.0M-$256.0M$111.0M-$73.5M-$43.0M-$25.1M-$12.9M
Stock-based compensation $60.0M$76.0M$73.0M$65.0M$55.0M$22.0M$9.0M$3.9M$495.0K$90.0K
Capital expenditure $2.0M$6.0M$24.0M$6.0M$26.0M$3.0M$1.9M$3.7M$5.5M$4.1M
Investing cash flow $66.0M-$84.0M$194.0M-$413.0M-$4.0M-$434.0M$59.2M-$113.4M-$49.1M-$38.9M
Financing cash flow $488.0M$277.0M$33.0M$33.0M$237.0M$439.0M$1.1M$129.1M$107.4M$70.1M
Buybacks ——————$94.0K$0——

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001724521-26-000025.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -400M -200M 0 200M 400M Net income, FY2016: -18M Revenue, FY2017: 1.4M Net income, FY2017: -53.1M Revenue, FY2018: 8.4M Net income, FY2018: -49.6M Revenue, FY2019: 15M Net income, FY2019: -84.7M Revenue, FY2020: 78M Net income, FY2020: -123M Revenue, FY2021: 383M Net income, FY2021: 53M Revenue, FY2022: 38M Net income, FY2022: -267M Revenue, FY2023: 37M Net income, FY2023: -307M Revenue, FY2024: 51M Net income, FY2024: -283M Revenue, FY2025: 33M Net income, FY2025: -353M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — $1.4M $8.4M $15.0M $78.0M $383.0M $38.0M $37.0M $51.0M $33.0M
Gross profit — — — — — — — — — —
Net income -$18.0M -$53.1M -$49.6M -$84.7M -$123.0M $53.0M -$267.0M -$307.0M -$283.0M -$353.0M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
  • Other event Item 8.01
  • Other event Item 8.01
  • Results announced Item 2.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%